Phytoformulation with hydroxycitric acid and capsaicin protects against high-fat-diet-induced obesity cardiomyopathy by reducing cardiac lipid deposition and ameliorating inflammation and apoptosis in the heart

Uddandrao, V. V. Sathibabu; Chandrasekaran, P.; Saravanan, G.; Brahmanaidu, Parim; Sengottuvelu, S.; Ponmurugan, P.; Vadivukkarasi, S.; Kumar, Umesh

doi:10.1016/j.jtcme.2023.08.004

Cited by 4 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with these findings, Kim et al found that simulation of TLR2 and TLR4 receptors and activation of the systemic inflammatory response in rabbits receiving a high-cholesterol diet accelerated the progression of both atherosclerotic cardiovascular disease and NAFLD, illuminating the importance of the chronic inflammatory response in the progression of cardiovascular disease and NAFLD in obese individuals [87]. On the other hand, it was found that inhibiting these signaling pathways and suppressing obesity-associated inflammation can ameliorate atherosclerosis, myocardial infarction, and cardiomyopathy in animal models [88][89][90]. Similarly, inhibition of NF-κB-mediated inflammatory response was shown to ameliorate myocardial injury in the mice model of NASH [91].…”

Section: Inflammationmentioning

confidence: 99%

The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases

Li,

Cui,

et al. 2024

Horm Metab Res

View full text Add to dashboard Cite

Obesity, non-alcoholic fatty liver disease (NAFLD), and atherosclerotic cardiovascular diseases are common and growing public health concerns. Previous epidemiological studies unfolded the robust correlation between obesity, NAFLD, and atherosclerotic cardiovascular diseases. Obesity is a well-known risk factor for NAFLD, and both of them can markedly increase the odds of atherosclerotic cardiovascular diseases. On the other hand, significant weight loss achieved by lifestyle modification, bariatric surgery, or medications, such as semaglutide, can concomitantly improve NAFLD and atherosclerotic cardiovascular diseases. Therefore, certain pathophysiological links are involved in the development of NAFLD in obesity, and atherosclerotic cardiovascular diseases in obesity and NAFLD. Moreover, recent studies indicated that simultaneously targeting several mechanisms by tirzepatide and retatrutide leads to greater weight loss and markedly improves the complications of metabolic syndrome. These findings remind the importance of a mechanistic viewpoint for breaking the association between obesity, NAFLD, and atherosclerotic cardiovascular diseases. In this review article, we mainly focus on shared pathophysiological mechanisms, including insulin resistance, dyslipidemia, GLP1 signaling, inflammation, oxidative stress, mitochondrial dysfunction, gut dysbiosis, renin-angiotensin-aldosterone system (RAAS) overactivity, and endothelial dysfunction. Most of these pathophysiological alterations are primarily initiated by obesity. The development of NAFLD further exacerbates these molecular and cellular alterations, leading to atherosclerotic cardiovascular disease development or progression as the final manifestation of molecular perturbation. A better insight into these mechanisms makes it feasible to develop new multi-target approaches to simultaneously unhinge the deleterious chain of events linking obesity and NAFLD to atherosclerotic cardiovascular diseases.

show abstract

Section: Inflammationmentioning

confidence: 99%

The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases

Li,

Cui,

et al. 2024

Horm Metab Res

View full text Add to dashboard Cite

show abstract

“…Hydroxycitric acid (HCA) treatment lowers blood cholesterol, obesity, and fatty acid synthesis (Roy et al, 2003). HCA lowers lipogenesis and biosynthesis of fatty acids, which result from reducing acetyl-CoA units by blocking ACLY (Uddandrao et al, 2023). In addition, HCA seems to upregulate the genes encoding serotonin receptors and raise endogenous serotonin concentrations.…”

Section: (-)-Hydroxycitric Acidmentioning

confidence: 99%

ATP-Citrate Lyase (ACLY): An Extensive Investigation from Molecular Insight to Therapeutic implications

Biju,

Chennam Lakshmikumar,

Rengasamy

2024

NRFHH

View full text Add to dashboard Cite

ATP Citrate Lyase (ACLY) is a central enzyme bridging carbohydrate metabolism and lipid biosynthesis, crucial for various physiological processes and implicated in numerous pathologies. This review comprehensively describes ACLY, a pivotal enzyme at lipid biosynthesis and cellular metabolism interface. It serves as crucial role for several physiological functions, making it a highly valued topic for research. Starting with a description of the biochemistry and molecular biology of ACLY, elucidating its structural features, functions, and regulatory mechanisms, particularly in lipid synthesis and histone acetylation. Considering the pathophysiological aspect, the review also examines the relationship between ACLY dysregulation and associated diseases, explaining its contribution to pathological conditions mechanistically. An explanation of ACLY inhibitors is as follows: an overview of these inhibitors, an understanding of their mechanisms of action, and an analysis of their effectiveness and specificity. The following sections transition from preclinical studies, summarising key findings and knowledge into therapeutic potential, to clinical trials. The review offers updated information about ACLY research, integrating data from multiple sources to give an in-depth understanding. It concludes with the challenges and outlook facing the developing ACLY inhibitors, considering the strategies to overcome these challenges and the upcoming path in research and development in this promising field. This comprehensive examination not only encapsulates the knowledge at present but also aims to inspire and guide future inquiries into the complex realm of ACLY and its potential as a therapeutic target, ultimately improving patient outcomes and quality of life.

show abstract

Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways

Tamilmani,

Sathibabu Uddandrao,

Chandrasekaran

et al. 2023

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

Phytoformulation with hydroxycitric acid and capsaicin protects against high-fat-diet-induced obesity cardiomyopathy by reducing cardiac lipid deposition and ameliorating inflammation and apoptosis in the heart

Cited by 4 publications

References 56 publications

The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases

The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases

ATP-Citrate Lyase (ACLY): An Extensive Investigation from Molecular Insight to Therapeutic implications

Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways

Contact Info

Product

Resources

About